Myovant Sciences Ltd (Myovant), a subsidiary of Sumitovant Biopharma Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids. In addition, it also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The company has operations in the US, Ireland, and Switzerland. Myovant is headquartered in London, the UK.
Headquarters
United Kingdom
Address
Ste 1 3rd Fl, 11/12 St. James's Square, London, SW1Y4LB
Website
myovant.com
Telephone
44 20 74003351
No of Employees
579
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$231.0M
Myovant Sciences Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Relugolix |
| MVT-602 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In June, the company announced a collaboration with Health in Her HUE to host Fighting Fibroids Together: A Candid Conversation Over Brunch in New Orleans, Louisiana. |
| 2022 | Contracts/Agreements | In October, the company entered into an agreement to sell its remaining stake to Sumitovant Biopharma. |
| 2022 | Others | In October, the company rejected US$2.5 billion takeover offer from Sumitovant Biopharma and its parent group Sumitomo Pharma Co Ltd. |
Competitor Comparison
| Key Parameters | Myovant Sciences Ltd | AbbVie Inc | AstraZeneca Plc | ObsEva SA | Evgen Pharma Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United Kingdom | Switzerland | United Kingdom |
| City | London | North Chicago | Cambridge | Plan-Les-Ouates | Netherton |
| State/Province | - | Illinois | England | - | England |
| No. of Employees | 579 | 50,000 | 89,900 | 15 | 7 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Myrtle Potter | Chairman | Executive Board | 2018 | 62 |
| David Marek | Chief Executive Officer; Director | Executive Board | 2021 | 56 |
| Matthew Lang | Chief Legal Officer; Chief Administrative Officer; General Counsel; Secretary | Senior Management | 2017 | 45 |
| Juan Camilo Arjona Ferreira | Chief Medical Officer | Senior Management | 2017 | 51 |
| Jeff Nornhold | Senior Vice President - Pharmaceutical Operations and Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward